References
- Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010; 16:387 - 97; http://dx.doi.org/10.1016/j.molmed.2010.07.002; PMID: 20692206
- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765 - 73; http://dx.doi.org/10.1056/NEJMoa0808710; PMID: 19228619
- Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207:339 - 44; http://dx.doi.org/10.1084/jem.20092506; PMID: 20142433
- Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118:599 - 601; http://dx.doi.org/10.1007/s00401-009-0595-z; PMID: 19798509
- Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12:1113 - 25; http://dx.doi.org/10.1093/neuonc/noq082; PMID: 20667896
- Zhai H, Heppner FL, Tsirka SE. Microglia/macrophages promote glioma progression. Glia 2011; 59:472 - 85; http://dx.doi.org/10.1002/glia.21117; PMID: 21264953
- Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg 1979; 50:305 - 11; http://dx.doi.org/10.3171/jns.1979.50.3.0305; PMID: 422981
- Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 2008; 8:377 - 86; http://dx.doi.org/10.1038/nrc2371; PMID: 18385683
- Huysentruyt LC, Akgoc Z, Seyfried TN. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme?. ASN Neuro 2011; 3:183 - 93; http://dx.doi.org/10.1042/AN20110011; PMID: 21834792
- Zheng PP, Severijnen LA, van der Weiden M, Willemsen R, Kros JM. Cell proliferation and migration are mutually exclusive cellular phenomena in vivo: implications for cancer therapeutic strategies. Cell Cycle 2009; 8:950 - 1; http://dx.doi.org/10.4161/cc.8.6.7851; PMID: 19229141
- Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 2006; 53:799 - 808; http://dx.doi.org/10.1002/glia.20334; PMID: 16541395
- Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:1624 - 36; http://dx.doi.org/10.1200/JCO.2003.05.063; PMID: 12697889
- Kofler J, Wiley CA. Microglia: key innate immune cells of the brain. Toxicol Pathol 2011; 39:103 - 14; http://dx.doi.org/10.1177/0192623310387619; PMID: 21078923
- Zheng PP, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 2007; 62:40 - 8; http://dx.doi.org/10.1002/ana.21151; PMID: 17503506
- Zheng PP, van der Weiden M, Kros JM. Hela l-CaD is implicated in the migration of endothelial cells/endothelial progenitor cells in human neoplasms. Cell Adh Migr 2007; 1:84 - 91; http://dx.doi.org/10.4161/cam.1.2.4332; PMID: 19329885
- Zheng PP, Weiden M, Sillevis Smitt PA, Luider TM, Kros JM. Hela /-CaD undergoes a DNA replication-associated switch in localization from the cytoplasm to the nuclei of endothelial cells/endothelial progenitor cells in human tumor vasculature. Cancer Biol Ther 2007; 6:886 - 90; http://dx.doi.org/10.4161/cbt.6.6.4091; PMID: 17582218